| Xanthohumol inhibits IL-12 production and reduces chronic allergic contact dermatitis. | |
| | |
MedLine Citation:
|
PMID: 20144742 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Xanthohumol (XN) and its related compounds were evaluated for their effects on modulating the production of interleukin (IL)-12, the most important factor driving T helper 1 immune responses. XN showed the strongest inhibitory effect on IL-12 production in macrophages stimulated by lipopolysaccharide (LPS) or LPS/interferon-gamma. Xanthohumol 4'-O-beta-D-glucopyranoside (XNG) inhibited IL-12 production less effectively than XN. Isoxanthohumol and 8-prenylnaringenin showed comparatively lower inhibitory effects on IL-12 production than XNG. (2S)-5-methoxy-8-prenylnaringenin 7-O-beta-D-glucopyranoside did not exert any effect on IL-12 production. We then tested how these compounds affected NF-kappaB binding activity to the kappaB site in the nucleus. The compounds inhibited kappaB binding in macrophages with the same potency order as IL-12 inhibition. Furthermore, we investigated whether XN, which showed the most effective reduction of IL-12 production, attenuated skin inflammation. Chronic allergic contact dermatitis, an experimental model for psoriasis, was used to determine the anti-inflammatory effects of XN in vivo. XN treatment reduced the degree of ear thickening induced by oxazolone. Taken together, XN might be effective as an anti-inflammatory agent to reduce skin inflammation by inhibiting IL-12 production. |
| | |
Authors:
|
Young-Chang Cho; Sung-Kyun You; Hyun Jung Kim; Cheong-Weon Cho; Ik-Soo Lee; Bok Yun Kang |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-02-06 |
Journal Detail:
|
Title: International immunopharmacology Volume: 10 ISSN: 1878-1705 ISO Abbreviation: Int. Immunopharmacol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-13 Completed Date: 2010-09-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100965259 Medline TA: Int Immunopharmacol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 556-61 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier B.V. All rights reserved. |
Affiliation:
|
College of Pharmacy & Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Cells, Cultured Chronic Disease Dermatitis, Allergic Contact / drug therapy*, immunology, physiopathology Female Flavonoids / administration & dosage, adverse effects, pharmacology* Humans Interferon-gamma / immunology Interleukin-12 / secretion* Lipopolysaccharides / immunology Macrophage Activation / drug effects Macrophages / drug effects*, immunology, metabolism, pathology Mice Mice, Inbred BALB C Mice, Inbred C57BL Models, Animal NF-kappa B / metabolism Oxazolone / administration & dosage Propiophenones / administration & dosage, adverse effects, pharmacology* Protein Binding Psoriasis / drug therapy*, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Flavonoids; 0/Lipopolysaccharides; 0/NF-kappa B; 0/Propiophenones; 15646-46-5/Oxazolone; 187348-17-0/Interleukin-12; 6754-58-1/xanthohumol; 82115-62-6/Interferon-gamma |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensate...
Next Document: Differential Anti-inflammatory and Anti-fibrotic Activity of Transplanted Mesenchymal vs. Hematopoie...